AIM ImmunoTech swaps $1.22M note for 5.07M shares
AIM ImmunoTech converted about $1.2 million of debt into 5.1 million shares, fully satisfying a promissory note held by Streeterville Capital.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. (AIM) entered into five exchange agreements with Streeterville Capital, LLC between August 31 and September 3, 2026 to address an existing promissory note dated February 16, 2024. Under these agreements, approximately $1,224,341 of the note was converted into 5,065,840 shares of common stock.
The exchanges were effected via corresponding partitioned promissory notes at an average conversion price of about $0.24 per share, and as of September 3, 2026 the promissory note was satisfied in full with no remaining amounts owed. Stockholders had previously approved the conversion or other satisfaction of this note on July 15, 2026 pursuant to NYSE American Company Guide Sections 713(a) and 713(b). The exchange shares were or will be issued under the Securities Act exemption in Section 3(a)(9) for exchanges with an existing security holder where no commission or other remuneration is paid for soliciting the exchange.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
4 items: 1.01, 1.02, 3.02, 9.01
4 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Debt converted: $1,224,341
Exchange shares issued: 5,065,840 shares
Average conversion price: $0.24 per share
+4 more
7 metrics
Debt converted
$1,224,341
Principal from the February 16, 2024 promissory note converted into equity under the exchange agreements
Exchange shares issued
5,065,840 shares
Common stock issued or to be issued to Streeterville Capital under the exchange agreements
Average conversion price
$0.24 per share
Approximate average price at which the promissory note amount was converted into common stock
Promissory note date
February 16, 2024
Original date of the promissory note exchanged into equity
Stockholder approval date
July 15, 2026
Special meeting at which stockholders approved conversion or satisfaction of the promissory note
Exchange agreement period start
August 31, 2026
Start date when AIM ImmunoTech began entering into the five exchange agreements
Exchange agreement period end
September 3, 2026
Date as of which AIM ImmunoTech reports the promissory note was satisfied in full
Key Terms
Exchange Agreements, Partitioned Promissory Notes, Promissory Note, Section 3(a)(9), +1 more
5 terms
Exchange Agreements financial
"entered into a total of five exchange agreements (the “Exchange Agreements”)"
A contractual arrangement where two or more parties agree to swap assets, securities, or obligations under specified terms and conditions, such as share-for-share exchanges, debt-for-equity conversions, or asset swaps. These agreements matter to investors because they change who owns what and how a company’s balance sheet and future cash flows look—think of it like two people trading items that can alter each person’s overall collection and resale value.
Partitioned Promissory Notes financial
"and, for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”)"
Promissory Note financial
"related to that certain Promissory Note dated February 16, 2024 (the “Promissory Note”)"
A promissory note is a written IOU in which one party promises to pay a specific sum, often with interest, to another party by a set date or on demand. Investors care because it functions like a loan: it creates a legal claim on future cash flows, carries credit and timing risk, and can affect valuation or liquidity—think of it as a formal, tradable promise to be repaid that can be assessed like any other debt investment.
Section 3(a)(9) regulatory
"provided by Section 3(a)(9) thereof as securities exchanged by the Company"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
NYSE American Company Guide Sections 713(a) and 713(b) regulatory
"pursuant to NYSE American Company Guide Sections 713(a) and 713(b), at a special meeting"
FAQ
What did AIM ImmunoTech (AIM) announce regarding its promissory note?
AIM ImmunoTech reported that it converted approximately $1,224,341 of a promissory note held by Streeterville Capital into 5,065,840 shares of common stock through five exchange agreements, and as of September 3, 2026 the promissory note was satisfied in full with no remaining amounts owed.
What was the average conversion price in AIM (AIM)’s exchange with Streeterville Capital?
The approximate average conversion price was $0.24 per share. At this price, AIM ImmunoTech converted about $1,224,341 of the outstanding balance under the February 16, 2024 promissory note into 5,065,840 shares of its common stock under the exchange agreements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
